Sotera Health Q1 2025 Earnings Report
Key Takeaways
Sotera Health reported a solid start to 2025 with net revenues increasing 2.6% to $255 million compared to the prior year quarter, driven by growth in the Sterigenics and Nordion segments. The company reported a net loss of $13 million, primarily due to a settlement related to ethylene oxide claims. Adjusted EBITDA saw an 8.8% increase, and Adjusted EPS grew by $0.01 to $0.14. The company reaffirmed its full-year 2025 outlook.
Net revenues increased 2.6% to $255 million in Q1 2025.
The company reported a net loss of $13 million, including a $31 million settlement.
Adjusted EBITDA grew by 8.8% to $122 million.
Adjusted EPS increased to $0.14 per diluted share.
Sotera Health
Sotera Health
Sotera Health Revenue by Segment
Forward Guidance
Sotera Health reaffirmed its full-year 2025 outlook with expectations for continued revenue and Adjusted EBITDA growth on a constant currency basis.
Positive Outlook
- Net revenues growth in the range of 4.0% to 6.0% on a constant currency basis.
- Adjusted EBITDA growth in the range of 4.5% to 6.5% on a constant currency basis.
- Updated foreign currency assumptions resulting in a lower headwind to net revenues (approximately 1.25%).
- Updated foreign currency assumptions resulting in a lower headwind to Adjusted EBITDA (approximately 1.50%).
- Weighted-average fully diluted share count in the range of 286 million to 287 million shares.
Challenges Ahead
- Interest Expense in the range of $155 million to $165 million.
- Tax rate applicable to Adjusted Net Income in the range of 33.0% to 35.0%.
- Capital expenditures in the range of $190 million to $210 million.
- Outlook is subject to various risks and uncertainties, including supply chain disruptions and regulatory changes.
- Inability to provide a reconciliation for non-GAAP financial measures on a forward-looking basis without unreasonable effort.
Revenue & Expenses
Visualization of income flow from segment revenue to net income